U.S. Markets open in 3 hrs 37 mins


Berlin - Berlin Delayed Price. Currency in EUR
7.31-0.04 (-0.57%)
As of 10:57AM CET. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.35
Bid7.06 x 0
Ask7.56 x 0
Day's Range7.31 - 7.32
52 Week Range3.67 - 17.36
Avg. Volume15
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateFeb 21, 2023 - Feb 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference

    RESEARCH TRIANGLE PARK, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on January 19th, 2023, at 11:30 AM EST, G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the virtual 2023 B. Riley Securities 3rd Annual Oncology Conference. The webcast of the event will be accessible on the Events & Presentations page of About G1 TherapeuticsG1 Therapeu

  • GlobeNewswire

    G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib

    - Initial Results from Pivotal Phase 3 PRESERVE 1 Trial in Colorectal Cancer Expected in February 2023; Positive Results Would Initiate Regulatory Interactions for Label Expansion - - Five Clinical Trials with Data Readouts in 2023 Will Evaluate Trilaciclib On-Target Effects of Myeloprotection and Enhanced Immune Function with Potential for Improved Efficacy Outcomes (Progression Free (PFS) and Overall Survival (OS)) - - Trilaciclib’s Potential Synergistic Effects with Chemotherapy, Antibody Dru

  • Benzinga

    G1 Therapeutics Reveals An Early Cut Data From Bladder Cancer Trial

    G1 Therapeutics Inc (NASDAQ: GTHX) provided an initial update on the PRESERVE 3 Phase 2 study of first-line platinum-based chemotherapy and maintenance therapy with avelumab, administered alone, or in combination with trilaciclib, in patients with untreated, locally advanced or metastatic urothelial carcinoma (mUC). Additional safety and efficacy data, including the primary endpoint of progression-free survival (PFS), are anticipated in the middle of 2023. The confirmed objective response rate (